Mikael Ørum
Chief Executive Officer at Acri Invest II ApS
Profile
Mikael Ørum is the founder of Cureon A (1999), Roche Innovation Center Copenhagen A (1998), Etexx Biopharmaceuticals (2003), Exiqon A (1995), Coegin Pharma AS (2005), Ventac Partners GmbH (2002), and Regenesance BV (2009).
He is also the founder of Ventac Partners LLC.
Currently, he holds the position of Chief Executive Officer at Acri Invest II ApS, Hamich ApS, and Managing Director & Partner at Ventac Partners A.
He is also the Chairman of CASiGEN Pharma Ltd., Neuroscience Technologies SLP, Neuroscience Technologies Ltd., Pharmacellion Ltd., and RhoVac ApS (since 2014).
Additionally, he serves as the Vice Chairman of Nansen Neuroscience Network.
In the past, he held the position of Chairman at Lifandis AS, Vice Chairman at Medicon Valley Alliance FMBA, and Director at Idogen AB and Orbit Genomics, Inc. He has an undergraduate degree from Copenhagen Business School, the University of Copenhagen, and Bankers Academy.
Mikael Ørum active positions
| Companies | Position | Start |
|---|---|---|
| Ventac Partners LLC | Founder | - |
Neuroscience Technologies SLP
 Neuroscience Technologies SLP Medical/Nursing ServicesHealth Services Neuroscience Technologies SLP provides medical research and laboratory services for neurosciences. The private company is based in Barcelona, ES and has subsidiaries in United Kingdom. The CEO of the Spanish company is Neil Thomas. | Chairman | - |
| Neuroscience Technologies Ltd. | Chairman | - |
| Nansen Neuroscience Network | Director/Board Member | - |
| CASiGEN Pharma Ltd. | Chairman | - |
| Pharmacellion Ltd. | Chairman | - |
| Acri Invest II ApS | Chief Executive Officer | - |
| Hamich ApS | Chief Executive Officer | - |
RhoVac ApS
 RhoVac ApS Pharmaceuticals: MajorHealth Technology Part of Chosa Oncology AB, RhoVac ApS is a Danish company that aims to prevent cancer recurrence and progression after primary tumor therapy. The company is based in Hørsholm, Denmark. The company's clinical phase II product, iCIP™ - Precision LiPlaCis® & DRP® with Breakthrough designation option, consists of LiPlaCis® and its Drug Response. Anders Månsson has been the CEO of the company since 2019. | Chairman | 2013-12-31 |
| ░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
Former positions of Mikael Ørum
| Companies | Position | End |
|---|---|---|
| ░░░░░ ░░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░ ░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░ | - |
| ░░░░░░░ ░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Training of Mikael Ørum
| Copenhagen Business School | Undergraduate Degree |
| University of Copenhagen | Undergraduate Degree |
| Bankers Academy | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| IDOGEN AB (PUBL) | Health Technology |
| Private companies | 21 |
|---|---|
Cureon A/S
 Cureon A/S Pharmaceuticals: MajorHealth Technology Cureon A/S is a Danish biotech company that owns the pharmaceutical rights to a novel DNA analogue, termed LNA (Locked Nucleic Acid) which displays unprecedented affinity compared to all other DNA chemistries. The company believes that the unique properties of this novel analogue will enable oligonucleotide based therapeutics (Antisense therapy) to enter main-stream pharmaceuticals. | Health Technology |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Health Technology |
Exiqon A/S
 Exiqon A/S Miscellaneous Commercial ServicesCommercial Services Exiqon A/S engages in the development of solutions for ribonucleic acid research and analysis through its Locked Nucleic Acid proprietary technology. Its products and services are used by researchers in academia, biotech, and pharmaceutical companies around the world to make discoveries about the correlation between gene activity and the development of disease. The company was founded by Mikael Ørum, Henrik Ørum and Troels Koch on November 1, 1995 and is headquartered in Copenhagen, Denmark. | Commercial Services |
Coegin Pharma AS
 Coegin Pharma AS Pharmaceuticals: MajorHealth Technology Coegin Pharma AS provides therapeutics that addresses inflammatory diseases. The company was founded by Berit Johansen on January 3, 2005 and is headquartered in Trondheim, Norway. | Health Technology |
| Etexx Biopharmaceuticals | |
Lifandis AS
 Lifandis AS Internet Software/ServicesTechnology Services Lifandis AS provides access to a wealth of biological samples. It offers data and biological material from the HUNT studies. The company was founded in 2007 and is headquartered in Levanger, Norway. | Technology Services |
Ventac Partners GmbH
 Ventac Partners GmbH Miscellaneous Commercial ServicesCommercial Services Ventac Partners GMBH offers life sciences consultancy services. Its consulting services include due diligence, education and training, market analysis, product development and valuation. The company was founded by Mikael Oerum in 2002 and is headquartered in Munich, Germany. | Commercial Services |
Medicon Valley Alliance FMBA
 Medicon Valley Alliance FMBA Miscellaneous Commercial ServicesCommercial Services Medicon Valley Alliance FMBA operates a life science cluster that spans across Denmark and Sweden. The non-profit company is based in the Medicon Valley region. | Commercial Services |
Regenesance BV
 Regenesance BV Drugstore ChainsRetail Trade Regenesance BV develops drugs for the treatment of neurodegenerative and immune mediated disorders. Its products include Regenemab, a monoclonal antibody for multiple indications like PNH, myasthenia gravis, amyotrophic lateral sclerosis, and multiples sclerosis. The company was founded by Valeria Ramaglia, Mikael Orum, Frank Baas and Kees Fluiter in 2009 is headquartered in Amsterdam, the Netherlands. | Retail Trade |
| CASiGEN Pharma Ltd. | |
| Ventac Partners LLC | |
Neuroscience Technologies SLP
Neuroscience Technologies SLP Medical/Nursing ServicesHealth Services Neuroscience Technologies SLP provides medical research and laboratory services for neurosciences. The private company is based in Barcelona, ES and has subsidiaries in United Kingdom. The CEO of the Spanish company is Neil Thomas. | Health Services |
| Neuroscience Technologies Ltd. | |
| Nansen Neuroscience Network | |
Ventac Partners A/S
 Ventac Partners A/S Miscellaneous Commercial ServicesCommercial Services Part of Ventac Partners GmbH, Ventac Partners A/S provides life science consulting services. The company is based in Copenhagen, Denmark. The CEO of the Danish company is Mikael Ørum. | Commercial Services |
| Pharmacellion Ltd. | |
| Acri Invest II ApS | |
| Hamich ApS | |
RhoVac ApS
RhoVac ApS Pharmaceuticals: MajorHealth Technology Part of Chosa Oncology AB, RhoVac ApS is a Danish company that aims to prevent cancer recurrence and progression after primary tumor therapy. The company is based in Hørsholm, Denmark. The company's clinical phase II product, iCIP™ - Precision LiPlaCis® & DRP® with Breakthrough designation option, consists of LiPlaCis® and its Drug Response. Anders Månsson has been the CEO of the company since 2019. | Health Technology |
RhoVac AB
 RhoVac AB BiotechnologyHealth Technology RhoVac AB opertaes as biotechnology company that engages in the research and development of immunotherapy. The firm develops therapeutic cancer vaccines. Its main focus is the development of a drug with the potential to prevent or limit the metastasis of metastatic cancers. The company was founded by Bo Anders Ljungqvist, Per Thor Straten, and Mads Hald Andersen in November 2015 and is headquartered in Lund, Sweden. | Health Technology |
Orbit Genomics, Inc.
 Orbit Genomics, Inc. Packaged SoftwareTechnology Services Orbit Genomics, Inc. operates as a technology platform for early disease detection, treatment, and prevention of diseases. The company is based in Boulder, CO. The company was founded by Elizabeth Willis, Harold Garner. Elizabeth Willis has been the CEO since incorporation. | Technology Services |
- Stock Market
- Insiders
- Mikael Ørum
